David L. Porter

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 17 papers. Top paper: “Decade-long leukaemia remissions with persistence of CD4+ CAR T cells”.

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Nature(2022)10.1038/s41586-021-04390-6

N/A

10.2DataRank · unranked

929 citations

Gregory M. Chen, Meng Wang, David L. Porter, Changya Chen, McKensie Collins +29 more

Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia

Hematology(2016)10.1182/asheducation-2016.1.567

N/A

9.6DataRank · unranked

223 citations

David L. Porter, Noelle V. Frey

Cytokine-mediated CAR T therapy resistance in AML

Nature Medicine(2024)10.1038/s41591-024-03271-5

N/A

2.2DataRank · unranked

90 citations

Leonel Torres, Olga Shestova, Maksim Shestov, Patrick Mellors, Han R Fisher +24 more

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Blood Advances(2024)10.1182/bloodadvances.2023012549

N/A

0.533DataRank · unranked

34 citations

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanová, Loretta J. Nastoupil +11 more

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help

Blood Advances(2023)10.1182/bloodadvances.2023010401

N/A

0.385DataRank · unranked

12 citations

Sarah Nikiforow, Carlos Bachier, Yen‐Michael S. Hsu, David G. Maloney, Marcela V. Maus +9 more

Decade-long remissions of leukemia sustained by the persistence of activated CD4 + CAR T-cells

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.07.443194

N/A

0.165DataRank · unranked

2 citations

Gregory M. Chen, Meng Wang, David L. Porter, Peng Gao, Shovik Bandyopadhyay +23 more

Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells

Research Square(2021)10.21203/rs.3.rs-505891/v1

N/A

0.104DataRank · unranked

1 citations

Gregory Chen, Meng Wang, David L. Porter, Peng Gao, Shovik Bandyopadhyay +23 more

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023010302

N/A

0DataRank · unranked

35 citations

Jessica Flynn, Mithat Gönen, Sean M. Devlin, Allison Parascondola, Ana Alarcón Tomás +17 more

Data from Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies

(2023)10.1158/1078-0432.c.6532514

N/A

0DataRank · unranked

0 citations

Wei‐Ting Hwang, Shannon L. Maude, David T. Teachey, Noelle V. Frey, Regina M. Myers +6 more

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Blood Advances(2022)10.1182/bloodadvances.2022008937

N/A

0DataRank · unranked

20 citations

Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel‐Angel Perales +10 more

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

Immunity(2023)10.1016/j.immuni.2023.09.001

N/A

0DataRank · unranked

171 citations

M. Ángela Aznar, Andrew J. Rech, Charly R. Good, Shunichiro Kuramitsu, Tong Da +15 more

Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis

Blood Advances(2024)10.1182/bloodadvances.2024014164

N/A

0DataRank · unranked

24 citations

Connor B. Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T. Maziarz +12 more

Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia

Haematologica(2024)10.3324/haematol.2024.285275

N/A

0DataRank · unranked

2 citations

Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O. Hexner, Ximena Bruno +13 more

Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.11.012

N/A

0DataRank · unranked

0 citations

Yimei Li, Shannon L. Maude, Elizabeth O. Hexner, Noelle V. Frey, David L. Porter +2 more

Evolving racial/ethnic disparities in AML survival in the novel therapy era

Blood Advances(2025)10.1182/bloodadvances.2024014127

N/A

0DataRank · unranked

14 citations

Phyllis A. Gimotty, Andrew Matthews, Ronac Mamtani, Selina M. Luger, Elizabeth O. Hexner +15 more

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Blood Advances(2022)10.1182/bloodadvances.2022008294

N/A

0DataRank · unranked

42 citations

Ana Alarcón Tomás, Jessica Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanová +10 more

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy

Molecular Therapy(2023)10.1016/j.ymthe.2023.01.012

N/A

0DataRank · unranked

59 citations

Silvia Beghi, Marco Ruella, Kalpana Parvathaneni, Silvano Salaris, Νεκτάριος Κωστόπουλος +23 more